Clinical aspects of autoimmune rheumatic diseases

The Lancet

Volumn 382, Issue 9894, 2013, Pages 797-808

  Goldblatt, Fiona ^a,b   O'Neill, Sean G ^c,d  

^a REPATRIATION GENERAL HOSPITAL   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d LIVERPOOL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; LA ANTIBODY; RO ANTIBODY; STEROID;

ACUTE HEART INFARCTION; ANTIBODY TITER; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; COLORECTAL CANCER; DERMATOMYOSITIS; DISEASE CLASSIFICATION; ENDOTHELIAL DYSFUNCTION; ESOPHAGUS CARCINOMA; GIANT CELL ARTERITIS; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE FUNCTION; HEMATOLOGIC MALIGNANCY; HUMAN; IDIOPATHIC INFLAMMATORY MYOSITIS; INTERSTITIAL LUNG DISEASE; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LUNG CANCER; LUNG EMBOLISM; LUNG FIBROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MICROANGIOPATHY; MICROSCOPIC POLYANGIITIS; MORTALITY; MYOSITIS; NONHODGKIN LYMPHOMA; OROPHARYNX CARCINOMA; OVARY CANCER; PANCREAS CANCER; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RHEUMATIC DISEASE; SJOEGREN SYNDROME; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; SYSTEMIC VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 84883128232     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61499-3     Document Type: Review

References (99)

1. Alarcon GS, Williams GV, Singer JZ, et al. Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease. J Rheumatol 1991; 18: 1332-39.
2. Williams HJ, Alarcon GS, Joks R, et al. Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol 1999; 26: 816-25.
3. Bodol ay E, Csiki Z, Szekanecz Z, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 2003; 21: 313-20.
4. Mosca M, Tani C, Talarico R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): simplified systemic autoimmune diseases. Autoimmun Rev 2011; 10: 256-58.
5. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-33.
6. Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapaa-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther 2011; 13: R30.
7. Julkunen H, Eronen M. L ong-term outcome of mothers of children with isolated heart block in Finland. Arthritis Rheum 2001; 44: 647-52.
8. Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58: 3902-12.
9. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 2010; 49: 1726-33.
10. Singh JA, Solomon DH, Dougados M, et al, and the Classification and Response Criteria Subcommittee of the Committee on Quality Measures, American College of Rheumatology. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum 2006; 55: 348-52.
11. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-77.
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
13. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-86.
14. Shiboski SC, Shiboski CH, Criswell L, et al, and the Sjogren's International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012; 64: 475-87.
15. Vitali C, Bombardieri S, Jonsson R, et al, and the European Study Group on Classification Criteria for Sjogren's Syndrome. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-58.
16. Whitcher JP, Shiboski CH, Shiboski SC, et al, and the Sjogren's International Collaborative Clinical Alliance Research Groups. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren's Syndrome International Registry. Am J Ophthalmol 2010; 149: 405-15.
17. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-05.
18. Silman AJ. Scleroderma. Baillieres Clin Rheumatol 1995; 9: 471-82.
19. Diot E, Giraudeau B, Diot P, et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest 1999; 116: 715-20.
20. Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980; 23: 617-25.
21. Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumato l 2010; 6: 112-16.
22. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-76.
23. Fransen J, Johnson SR, van den Hoogen F, et al. Items for developing revised classification criteria in systemic sclerosis: results of a consensus exercise. Arthritis Care Res (Hoboken) 2012; 64: 351-57.
24. Johnson SR, Fransen J, Khanna D, et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 2012; 64: 358-67.
25. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292 : 344-47.
26. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-07.
27. Shamim EA, Rider LG, Pandey JP, et al. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 2002; 46: 1885-93.
28. O'Hanlon TP, Carrick DM, Targoff IN, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006; 85: 111-27.
29. Vincze M, Danko K. Idiopathic inflammatory myopathies. Best Pract Res Clin Rheumatol 2012; 26: 25-45.
30. Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 1990; 33: 1065-67.
31. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
32. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013; 65: 1-11.
33. Helmick CG, Felson DT, Lawrence RC, et al, and the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthriti s Rheum 2008; 58: 15-25.
34. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006; 15: 308-18.
35. Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995; 38: 551-58.
36. Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999; 42: 46-50.
37. Voss A, Green A, Junker P. Systemic lupus erythematosus in Denmark: clinical and epidemiological characterization of a county-based cohort. Scand J Rheumat ol 1998; 27: 98-105.
38. Ward MM. Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: results from the third national health and nutrition examination survey. J Womens Health (Larchmt) 2004; 13: 713-18.
39. Hochberg MC, Perlmutter DL, Medsger TA, et al. Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA. Lupus 1995; 4: 454-56.
40. Villa-Blanco I, Calvo-Alen J. Utilizing registries in systemic lupus erythematosus clinical research. Expert Rev Clin Immunol 2012; 8: 353-60.
41. Guerra SG, Vyse TJ, Cunninghame Graham DS. The genetics of lupus: a functional perspective. Arthritis Res Ther 2012; 14: 211.
42. Wahren-Herlenius M, Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013; 382: 819-31.
43. Alonso-Perez E, Suarez-Gestal M, Calaza M, et al, and the European Consortium of SLE DNA Collections. Further evidence of subphenotype association with systemic lupus erythematosus susceptibility loci: a European cases only study. PLoS One 2012; 7: e45356.
44. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008; 37: 223- 35.
45. Walker UA, Tyndall A, Czirjak L, et al, and the EUSTAR co-authors. Geographical variation of disease manifestations in systemic sclerosis: a report f rom the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis 2009; 68: 856-62.
46. Steen V, Domsic RT, Luc as M, Fertig N, Medsger TA Jr. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum 2012; 64: 2986-94.
47. Broen JC, Coenen MJ, Radstake TR. Genetics of systemic sclerosis: an update. Curr Rheum atol Rep 2012; 14: 11-21.
48. Martin JE, Bossini-Castillo L, Martin J. Unraveling the genetic component of systemic sclerosis. Hum Genet 2012; 131: 1023-37.
49. Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003; 48: 1956-63.
50. McCormic ZD, Khuder SS, Aryal BK, Ames AL, Khuder SA. Occ upational silica exposure as a risk factor for scleroderma: a meta-analysis. Int Arch Occup Environ Health 2010; 83: 763-69.
51. Aryal BK, Khuder SA, Schaub EA. Meta-analysis of systemic sclerosis and exposure to solvents. Am J Ind Med 2001; 40: 271-74.
52. van der Meulen MF, Bronner IM, Hoogendijk JE, et al. Pol ymyositis: an overdiagnosed entity. Neurology 2003; 61: 316-21.
53. Ntatsaki E, Watts RA, Scott DG. Epidemiology of ANCA-associated vasculitis. Rheum Dis Clin North Am 2010; 36: 447-61.
54. Richards BL, March L, Gabriel SE. Epidemiology of large-vessel vasculidities. Best Pract Res Clin Rheumatol 2010; 24: 871-83.
55. Lawrence RC, Felson DT, Helmick CG, et al, and the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58: 26-35.
56. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12: 204-12.
57. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-25.
58. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-57.
59. Cervera R, Khamashta MA, Font J, et al, and the European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality i n systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients. Medicine (Baltimore) 2003; 82: 299-308.
60. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in syste mic lupus erythematosus [see comment]. Arthritis Rheum 2001; 44: 2331-37.
61. O'Neill SG, Pego-Reigosa JM, Hingorani AD, Bessant R, Isenberg DA, Rahman A. Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 2009; 48: 573-75.
62. Bruce IN. 'Not only but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 1492-502.
63. Au K, Singh MK, Bodukam V, et al. Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. Arthritis Rheum 2011; 63: 2078-90.
64. Nussinovitch U, Shoenfeld Y. Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality. Autoimmun Rev 2011; 10: 259-66.
65. Ngian GS, Sahhar J, Wicks IP, Van Doornum S. Cardiovascular disease in systemic sclerosis - an emerging association? Arthritis Res Ther 2011; 13: 237.
66. Plazak W, Kopec G, Tomkiewicz-Pajak L, et al. Heart structure and function in patients with generalized autoimmune diseases: echocardiography with tissue Doppler study. Acta Cardiol 2011; 66: 159-65.
67. Zoller B, Li X, Sundquist J, Sundquist K. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PLoS One 2012; 7: e33442.
68. Zoller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012; 379: 24 4-49.
69. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-47.
70. Ekstrom Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008; 111: 4029-38.
71. Bernatsky S, Ramsey- Goldman R, Rajan R, et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 1507-09.
72. Dias C, Isenberg DA. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lym phoma. Nat Rev Rheumatol 2011; 7: 360-68.
73. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006; 65: 796-803.
74. Tzioufas AG, Voulgarelis M. Update on Sjogren's syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol 2007; 21: 989-1010.
75. Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1481-90.
76. Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev 2011; 10: 248-55.
77. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006; 33: 1113-16.
78. Pontifex EK, Hill CL, Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 2007; 66: 551-53.
79. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish popula tion-based cohort study. Br J Cancer 2001; 85: 41-45.
80. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96-100.
81. Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64: 523-32.
82. Merrell M, Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis 1955; 1: 12-32.
83. O'Neill S, Cervera R. Systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2010; 24: 841-55.
84. Urowitz MB, Gladman DD, Tom BD, Ibanez D, Farewell VT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008; 35: 2152-58.
85. Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 20 12; 64: 4021-28.
86. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20-28.
87. Malladi AS, Sack KE, Shiboski SC, et al. Primary Sjogren's syndrome as a systemic disease: a study of participants enrolled in an international Sjogren's syndrome registry. Arthritis Care Res (Hoboken) 2012; 64: 911-18.
88. Newton JL, Frith J, Powell D, et al, and the UK primary Sjogren's syndrome registry. Autonomic symptoms are common and are associat ed with overall symptom burden and disease activity in primary Sjogren's syndrome. Ann Rheum Dis 2012; 71: 1973-79.
89. Bjerrum K, Prause JU. Primary Sjogren's syndrome: a subjective description of the disease. Clin Exp Rheumatol 1990; 8: 283-88.
90. Sutcliffe N, Stoll T, Pyke S, Isenberg DA. Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjogren's syndrome (SS), and primary SS. J Rheumatol 1998; 25: 63-68.
91. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002; 46: 741-47.
92. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39: 269-77.
93. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-44.
94. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
95. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Res pir Crit Care Med 2008; 177: 1248-54.
96. Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013; 52: 155-60.
97. Le Pavec J, Girgis RE, Lechtzin N, et al. Systemic sclerosis-related pulmonary hypertension as sociated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 2011; 63: 2456-64.
98. Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 2002; 41: 22-26.
99. Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 2001; 28: 2230-37.